Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers. We investigated the association between these three GST polymorphisms and breast cancer risk using existing data from 718 women BRCA1 and BRCA2 mutation carriers from Australia, the UK, Canada, and the USA. Data were analyzed within a proportional hazards framework using Cox regression. There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites. These results support the need for replication studies to confirm or refute hypothesis-generating studies.

Original publication

DOI

10.1007/s10549-009-0601-0

Type

Journal article

Journal

Breast cancer research and treatment

Publication Date

07/2010

Volume

122

Pages

281 - 285

Addresses

Division of Genetics and Population Health, Queensland Institute of Medical Research, 300 Herston Rd, Herston 4006, Australia.

Keywords

kConFab, EMBRACE, INHERIT, MAGIC, Humans, Breast Neoplasms, Neoplastic Syndromes, Hereditary, Genetic Predisposition to Disease, Glutathione Transferase, Incidence, Proportional Hazards Models, Risk, Amino Acid Substitution, Gene Deletion, Genotype, Heterozygote, Polymorphism, Single Nucleotide, Genes, BRCA1, Genes, BRCA2, Female, Glutathione S-Transferase pi, Ethnicity